Aakash Desai: MYC IHC could be crucial in tailoring immunotherapy approaches in NSCLC
Aakash Desai, shared a post on LinkedIn:
“Monday Read out in the Lung Cancer Journal ESMO- European Society for Medical Oncology.
Our recent publication explores the “Predictive value of MYC IHC in NSCLC with IO.
Key Insights:
➡ Positive MYC IHC is a promising marker for predicting overall survival (OS) following immuno therapy.
➡ Cases with MYC positive and PD-L1 negative status exhibit notably shorter OS, spotlighting a critical subgroup for potential therapeutic focus.
Our study suggests that MYC IHC, more than MYC copy number gain, could be crucial in tailoring immunotherapy approaches, possibly enhancing patient outcomes in non-small cell lung cancer (NSCLC).
More prospective studies are needed in this space to outline MYC’s role as a true biomarker of immuno therapy in NSCLC.
Authors: Julia Naso, Aakash Desai, Caleb J. Smith, Yash P. Ashara , Stephen Yip, and Ying-Chun Lo.
Source: Aakash Desai/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023